IP Library Granted Patent US 7,411,029
Granted Patent B2
US 7,411,029 · App. 10/876,969 · Granted Aug 12, 2008

Prepolymers for improved surface modification of contact lenses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,411,029
App. No.
10/876,969
Granted
Aug 12, 2008
Kind
B2
Abstract

Provided are a novel class of fumaric- and itaconic-containing prepolymers and compositions comprising the prepolymers used in the manufacture of medical devices.

Claims (40)

1. A prepolymer selected from the group consisting of compounds having the following formula:

YCO—CH═CHCOW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOCCH═CH—COY

CH 2 ═C(CH 2 COY)COW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOC(CH 2 COY)C═CH 2

and

CH 2 ═C(CH 2 COY)COW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOCCH 2 (COY)C═CH 2

wherein R 1 is selected from the group consisting of alkylenes and alkylenes containing ether linkages, R 2 and R 3 are independently alkyl or phenyl groups, unsubstituted or substituted with halogen and ether linkages, W is O or NH, m is an integer between 2 and 200, and Y is a residue derived from a reactive oligomer of hydrophilic monomers.

2. The prepolymer of claim 1 wherein R 1 contains 1-10 carbon atoms.

3. The prepolymer of claim 1 wherein the compound has the following formula:

YCO—CH═CHCOW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOCCH═CH—COY

wherein R 1 is selected from the group consisting of alkylenes and alkylenes containing ether linkages, R 2 and R 3 are methyl, m is an integer between 5 and 200, W is O and Y is a residue derived from a reactive oligomer derived from hydrophilic monomers selected from the group consisting of amide, hydroxyl and zwitterionic containing hydrophilic monomers and is in a trans configuration.

4. The prepolymer of claim 1 wherein the compound has the following formula:

YCO—CH═CHCOW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOCCH═CH—COY

wherein R 1 is selected from the group consisting of alkylenes and alkylenes containing ether linkages, R 2 and R 3 are methyl, m is an integer between 5 and 200, W is O and Y is a residue derived from a reactive oligomer derived from hydrophilic monomers selected from the group consisting of amide, hydroxyl and zwitterionic containing hydrophilic monomers and is in a cis configuration.

5. The prepolymer of claim 1 wherein the compound has the following formula:

CH 2 ═C(CH 2 COY)COW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOC(CH 2 COY)C═CH 2

or

CH 2 ═C(CH 2 COY)COW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOCCH 2 (COY)C═CH 2

wherein R 1 is selected from the group consisting of alkylenes and alkylenes containing ether linkages, R 2 and R 3 are methyl, m is an integer between 5 and 100, W is O and Y is a residue derived from a reactive oligomer derived from hydrophilic monomers selected from the group consisting of amide, hydroxyl and zwitterionic containing hydrophilic monomers.

6. The prepolymer of claim 1 wherein the compound has the following formula:

YCO—CH═CHCOW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOCCH═CH—COY

wherein R 1 is selected from the group consisting of alkylenes and alkylenes containing ether linkages, R 2 and R 3 are methyl, m is an integer between 5 and 200, W is O and Y is a residue derived from a reactive oligomer derived from an ethylenically unsaturated lactam containing monomer and is in a trans configuration.

7. The prepolymer of claim 1 wherein the compound has the following formula:

YCO—CH═CHCOW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOCCH═CH—COY

wherein R 1 is selected from the group consisting of alkylenes and alkylenes containing ether linkages, R 2 and R 3 are methyl, m is an integer between 5 and 200, W is O and Y is a residue derived from a reactive oligomer derived from an ethylenically unsaturated lactam containing monomer and is in a cis configuration.

8. The prepolymer of claim 1 wherein the compound has the following formula:

CH 2 ═C(CH 2 COY)COW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOC(CH 2 COY)C═CH 2

or

CH 2 ═C(CH 2 COY)COW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOCCH 2 (COY)C═CH 2

wherein R 1 is selected from the group consisting of alkylenes and alkylenes containing ether linkages, R 2 and R 3 are methyl, m is an integer between 5 and 100, W is O and Y is a residue derived from a reactive oligomer derived from an ethylenically unsaturated lactam containing monomer.

9. The prepolymer of claim 1 wherein the compound has the following formula:

YCO—CH═CHCOW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOCCH═CH—COY

wherein R 1 is selected from the group consisting of alkylenes and alkylenes containing ether linkages, R 2 and R 3 are methyl, m is an integer between 5 and 200, W is O and Y is a residue derived from a reactive oligomer derived from N-vinylpyrrolidone and is in a trans configuration.

10. The prepolymer of claim 1 wherein the compound has the following formula:

YCO—CH═CHCOW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOCCH═CH—COY

wherein R 1 is selected from the group consisting of alkylenes and alkylenes containing ether linkages, R 2 and R 3 are methyl, m is an integer between 5 and 200, W is O and Y is a residue derived from a reactive oligomer derived from N-vinylpyrrolidone and is in a cis configuration.

11. The prepolymer of claim 1 wherein the compound has the following formula:

CH 2 ═C(CH 2 COY)COW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOC(CH 2 COY)C═CH 2

or

CH 2 ═C(CH 2 COY)COW(R 1 )(SiR 2 R 3 O) m (SiR 2 R 3 )(R 1 )WOCCH 2 (COY)C═CH 2

wherein R 1 is selected from the group consisting of alkylenes and alkylenes containing ether linkages, R 2 and R 3 are methyl, m is an integer between 5 and 100, W is O and Y is a residue derived from a reactive oligomer derived from N-vinylpyrrolidone.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Nov 18, 2008
From: BAUSCH & LOMB INCORPORATED; WP PRISM, INC.; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; EYEONICS, INC.
To: CREDIT SUISSE
Reel/Frame 021849/0244 →
SECURITY AGREEMENT Recorded Nov 16, 2007
From: BAUSCH & LOMB INCORPORATED; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; IOLAB CORPORATION; RHC HOLDINGS, INC.; WP PRISM, INC.
To: CREDIT SUISSE
Reel/Frame 020122/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2004
From: LAI, YU-CHIN; QUINN, EDMOND T.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 015154/0628 →